Palisade Bio Begins Dosing First Patients in Phase 1b Trial of PALI-2108, an Oral First-In-Class PDE4 Inhibitor Prodrug for Fibrostenotic Crohn’s Disease Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Source: Globenewswire
Palisade Bio's Clinical Development: Palisade Bio has initiated a Phase 1b clinical study for PALI-2108, a novel PDE4 inhibitor prodrug targeting fibrostenotic Crohn’s disease (FSCD), with topline data expected in Q1 2026.
Mechanism and Study Design: The study will assess safety, pharmacokinetics, and pharmacodynamics in 6 to 12 patients over 14 days, utilizing advanced techniques like RNA sequencing to evaluate treatment effects on inflammatory and fibrotic pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
